In an exciting announcement from San Francisco, NeuroAge Therapeutics has launched its revolutionary NeuroAge Test, a cutting-edge assessment that employs advanced AI, MRI technology, and both genetic and cognitive analysis to forecast biological brain age and dementia risk decades before symptoms manifest. This innovative tool aims to empower individuals to take proactive steps towards maintaining their cognitive health by delivering personalized reports and actionable recommendations.

Dr. Christin Glorioso, CEO and Co-founder of NeuroAge Therapeutics, emphasized the breakthrough nature of this test, stating, "The NeuroAge Test represents a significant breakthrough in how we approach brain aging. Our test empowers individuals to take control of their cognitive health by giving them the data-driven insights needed to maintain optimal brain function as they age."

Globally, the impact of dementia is staggering, with over 55 million people currently living with the condition. Alzheimer's disease, which is responsible for 60-70% of dementia cases, sees risk levels double approximately every five years post-65 years of age. The NeuroAge Test is strategically designed to identify early markers of cognitive decline, making earlier interventions possible and paving the way for improved brain health management.

What sets the NeuroAge Test apart from traditional cognitive assessments is its comprehensive approach. It evaluates three distinct types of brain aging: structural, functional, and molecular. This depth of analysis allows for a more nuanced understanding of brain health and tailored strategies for intervention.

Key Features of the NeuroAge Test Include:

1. **Cognitive Testing (NeuroGames):** Engaging interactive challenges that assess memory, attention, and processing speed.

2. **Blood Biomarkers Analysis:** Analyzing 52 RNA levels predictive of brain aging, offering insights that can lead to early intervention.

3. **Genetic Profiling:** Utilizing whole genome DNA testing to screen for over 300 genetic markers associated with neurodegenerative diseases, including rare familial mutations linked to Alzheimer's, Parkinson's, vascular dementia, and frontotemporal dementia.

4. **Brain MRI:** Employing advanced imaging technology to provide a detailed, 3D view of cognitive health.

To celebrate the launch, NeuroAge Therapeutics will host an event on December 5th, 2024, at MBC Biolabs in San Francisco. Attendees will learn more about the test’s revolutionary capabilities and gain insights from expert presentations focused on strategies for preserving cognitive health and preventing decline.

Event Details:

- **Date:** December 5th, 2024

- **Time:** 5:30 PM - 8:30 PM

The NeuroAge Test is not just a diagnostic tool; it represents a shift in how we think about aging and cognitive health. Proceeds from test purchases will support vital research into neurodegenerative diseases and cognitive health initiatives.

NeuroAge Therapeutics was founded by Dr. Christin Glorioso, who was inspired to create a solution after witnessing the devastating effects of Alzheimer’s disease on her grandparent. With a mission to combat age-related cognitive decline, NeuroAge is forging ahead with innovative therapies and prognostic tools.

For more information and media inquiries, feel free to visit NeuroAge's website or contact Dr. Glorioso directly.

Don’t miss this incredible opportunity to learn how to protect your brain for the future!